We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 68

Patent misuse in the pharmaceutical industry: developments in US & EU

  • Wragge Lawrence Graham & Co LLP
  • -
  • European Union, USA
  • -
  • October 31 2007

The pharmaceutical industry has been scrutinised closely by competition authorities and courts in the US and Europe

EU, US regulators ease process for orphan drugs

  • Gowling Lafleur Henderson LLP
  • -
  • European Union, USA
  • -
  • December 6 2007

In an effort to encourage development of drug treatments for rare diseases, the European Commission, the European Medicines Agency and the U.S. Food and Drug Administration announced steps to streamline the application process for orphan drugs

The patentability of stem cells: WARF's success and failure on opposite sides of the Atlantic

  • Shepherd & Wedderburn LLP
  • -
  • European Union, United Kingdom, USA
  • -
  • March 31 2008

The Wisconsin Alumni Research Foundation (WARF) has had three of its patents in relation to stem cells (and in particular, methods of isolation) upheld by the United States Patent and Trademark Office (USPTO

U.S. and EU authorities focus attention on competition in pharmaceutical industry

  • Hogan Lovells
  • -
  • European Union, USA
  • -
  • March 25 2008

During the past several years, there has been an increase in antitrust enforcement directed at the pharmaceutical industry, both in the United States and in Europe, primarily focused on conduct by branded pharmaceutical companies that might affect the timing and effectiveness of entry by less costly generic drugs

Definitions of generic competition in contracts

  • Fasken Martineau DuMoulin LLP
  • -
  • European Union, USA
  • -
  • April 6 2009

In licensing and other collaborations the onset of 'generic competition' may be cause for renegotiation of certain aspects of the agreement or reductions in payments

Product and disease registries: planning for data protection

  • McDermott Will & Emery
  • -
  • European Union, USA
  • -
  • April 10 2007

Biopharmaceutical companies have now seen the power of post-market approval and observational registries

A clinical trial data sharing commitment between the EU and the US

  • Baker & McKenzie
  • -
  • European Union, USA
  • -
  • August 19 2013

The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the US Pharmaceutical Research and Manufacturers of America (PhRMA

European Union negotiations reach agreement on new clinical trials regulation

  • Ropes & Gray LLP
  • -
  • European Union, USA
  • -
  • January 22 2014

The European Union ("EU") has cleared the way for adoption of a new clinical trials regulation within the EU. On December 20, 2013, the Committee of

Recent developments in biosimilars: Canada, EU, France and the U.S.

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada, European Union, France, USA
  • -
  • January 29 2014

There have been a number of developments in biosimilars of late, including regulatory approvals in Canada issued on January 15, 2014 for two

When food production leads to prosecution

  • Davis Wright Tremaine LLP
  • -
  • European Union, USA
  • -
  • March 6 2013

Over the last few weeks, two big stories have made headlines in the food industry. Beginning in early February, news media across Europe began